Journal of Patient Safety & Quality Improvement

Journal of Patient Safety & Quality Improvement

A Critical Analysis Study of Pharmacological and Clinical Information Provided in Drug Package Inserts Based on Drugs and Cosmetics Rules Guidelines

Document Type : Original Article

Authors
Jambusayee Jeyasudha 1
Gomathisankar Rajeshkumar 2
1 Assistant Professor of Pharmacology, Government Kilpauk Medical College, Chennai-600 010 Tamilnadu,India
2 Assistant Professor of Pharmacology, Government Kilpauk Medical College, Chennai-600010, Tamilnadu, India
10.22038/psj.2021.58640.1332
Abstract
Introduction:
Drug package inserts are officially approved documents provided along with the drugs by the drug marketing company. They act as an important source of information about the drug for both patients and physicians, which helps in proper administration and improving the safe use of medications. The pharmacological and clinical information presented in them for its consistency and completeness were analyzed in this study.
Materials and Methods:
The drug package inserts were collected and analyzed for the pharmacological and clinical information, based on the headings under Section 6.2 & Section 6.3 mentioned in Schedule D of Drugs and Cosmetics Act and Rules, 1945. The drug package inserts that were analyzed in this study included different drug formulations and drugs belonging to different systems.
Results:
This study shows that the generic name, the brand name of the drug, its active ingredient, therapeutic uses, dosage form, and manufacturer details are present in all the package inserts (100%). But details about safety and precautions are given only in about 90%. Information about pharmacokinetics, pharmacodynamics, pharmaceutical particulars, and the antidote for drug overdose are missing in many package inserts.
Conclusion:
From our study, we conclude that a majority of the package inserts provide adequate details regarding key information. However, we recommend mentioning the approximate cost of the drug, references for the information provided in it, along with the Toll-free number of the Pharmacovigilance Programme of India (PVPI) for reporting adverse drug effects.
Keywords
Drug package inserts
Drug information
Schedule D
Pharmacovigilance
  1. WHO, “Trade, foreign policy, diplomacy, and health,” (http://www. who.int/trade/ glossary/ story 073/en/# main.)
  2. Lal, “Pharmaceutical drug promotion: how it is being practiced in India?” The Journal of the Association of Physicians of India, 2001: 49: 266–273,
  3. World Health Organization (WHO), Ethical Criteria for Medicinal Drug Promotion, WHO, Geneva, 1988
  4. of India, Ministry of Health and Family Welfare. Drug and Cosmetics Rules, 1945. Available at: http:// cdsco. nic.in/ html/ DrugsandCosmeticAct.pdf.
  5. Dass E. A study of clinical information of various packages inserts: an approach to encourage adverse drug reaction reporting and emphasis on black box warning. Int J Basic Clin Pharmacol, 2018; 7:1232-7
  6. Zaghi D, Maibach HI. Survey of safety and efficacy information in drug inserts for topical prescription medications. Am J Clin Dermatol, 2007; 8(1):43-6.
  7. Chhaya MU. Analysis of package inserts of orally administered drugs available in the Indian market. Int J Res Med Sci, 2017; 5:529-32.
  8. Deepak Ramdas,  Ananya Chakraborty ,   Swaroop HS,  Syed Faizan, Praveen Kumar V,  and Srinivas BN. A Study of Package Inserts in Southern India J Clin Diagn Res, 2013; 7(11): 2475-2477.
  9. Shivkar Y M. Clinical information in drug package inserts in India. J Postgrad Med, 2009; 55:104-7
  10. Storflor J, Pettersen L, Slørdal L, Spigset O. Drug package inserts--varying information for the same medicines. Tidsskr Nor Laegeforen, 2013; 133(9):955-9.
  11. Gurpreet Kaur Randhawa et al. A Critical Analysis of Claims and Their Authenticity in Indian Drug Promotional Advertisements. Advances in Medicine, 2015; 4: 469147.
  12. Sharma S, Akhoon N, Moe HW, Nair DR, Shashidhar V. A study of perceptions and exposure of drug promotional literature among clinicians in a teaching hospital. Perspect Clin Res, [Epub ahead of print]
  13. Singh KR, Munshi R and Arora D: Assessment of the Degree of Awareness among Physicians and Patients about Drug Package Inserts. Int J Pharm Sci Res, 2016; 7(3): 1338-42.
  14. Jignesh K. Ved. Package Inserts in India: Need for a Revision. International Journal of Pharma Sciences and Research, 2010; 1(11): 454-456.
  15. Vivekanandan Kalaiselvan, Prasad Thota, and Gyanendra Nath Singh.Pharmacovigilance Programme of India: Recent developments and future perspectives.Indian J Pharmacol 2016; 48(6): 624–628.
  16. Sudha MJ, Viveka S, Remya S, Udupa AL. Drug package inserts: how accessible is the information? Int J Basic Clin Pharmacol, 2015; 4: 1132-5.

 

 



 

 

Journal of Patient Safety & Quality Improvement
Volume 9, Issue 3
Summer 2021
Pages 183-187